Status:
COMPLETED
Alefacept (Amevive) With or Without Narrowband UVB Treatment in Patients With Psoriasis.
Lead Sponsor:
Medical University of Graz
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Alefacept is a new anti-psoriatic drug within the group of the so-called biologics. In about 30% of patients alefacept induces a more than 75% improvement of psoriasis after a 12-week treatment period...
Detailed Description
Psoriasis is an inflammatory skin disease that affects an estimated 2% to 3% of the world's population. There are a wide range of local and systemic clinical treatments and agents for clearing, or at ...
Eligibility Criteria
Inclusion
- Moderate to severe plaque-type psoriasis;
- disease duration for more than 6 months
- PASI above 10.
Exclusion
- age \< 18 years;
- pregnancy or lactation;
- presence of a dysplastic nevus syndrome;
- photosensitive skin disease;
- autoimmune disease;
- severe renal or hepatic disease;
- presence or history of malignant skin tumors;
- presence of antinuclear antibodies;
- history of previous treatments with arsenic, methotrexate, or x-rays;
- within the last 4 weeks before enrollment into the study, UVB or PUVA treatment, immunosuppressive/-modulating drugs (such as corticosteroids, cyclosporine, and biologics such as infliximab, etanercept or efalizumab).
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2004
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00407342
Start Date
February 1 2004
End Date
September 1 2004
Last Update
September 30 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Graz
Graz, Styria, Austria, A-8036